Zai Lab Ltd
ZLAB18.000USD
+1.020+6.01%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
1.99BValor de mercado
PerdaP/L TTM
Mais detalhes de Zai Lab Ltd Empresa
Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
Informações de Zai Lab Ltd
Código da empresaZLAB
Nome da EmpresaZai Lab Ltd
Data de listagemSep 28, 2020
CEODu (Ying)
Número de funcionários1869
Tipo de títulosDepository Receipt
Fim do ano fiscalSep 28
EndereçoBuilding B, 899 Halei Road, Pudong
CidadeSHANGHAI
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísChina
Código postal201203
Telefone862161632588
Sitehttps://www.zailaboratory.com/
Código da empresaZLAB
Data de listagemSep 28, 2020
CEODu (Ying)
Executivos da empresa Zai Lab Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. John David Diekman, Ph.D.
Dr. John David Diekman, Ph.D.
Lead Independent Director
Lead Independent Director
99.77K
+10831.00%
Mr. Joshua L. Smiley
Mr. Joshua L. Smiley
President, Chief Operating Officer
President, Chief Operating Officer
86.60K
+10000.00%
Mr. William David (Bill) Lis
Mr. William David (Bill) Lis
Independent Director
Independent Director
35.11K
-2983.00%
Dr. Yajing Chen, Ph.D.
Dr. Yajing Chen, Ph.D.
Chief Financial Officer
Chief Financial Officer
17.44K
-240.00%
Dr. Ying (Samantha) Du, Ph.D.
Dr. Ying (Samantha) Du, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Ms. Leung (Nisa Bernice) Wing-Yu
Ms. Leung (Nisa Bernice) Wing-Yu
Independent Director
Independent Director
--
--
Mr. Peter Karl Wirth, J.D.
Mr. Peter Karl Wirth, J.D.
Independent Director
Independent Director
--
--
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Independent Director
Independent Director
--
--
Mr. Frazor Titus Edmondson, J.D.
Mr. Frazor Titus Edmondson, J.D.
Company Secretary, Chief Legal Officer
Company Secretary, Chief Legal Officer
--
--
Mr. Scott W. Morrison, CPA
Mr. Scott W. Morrison, CPA
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. John David Diekman, Ph.D.
Dr. John David Diekman, Ph.D.
Lead Independent Director
Lead Independent Director
99.77K
+10831.00%
Mr. Joshua L. Smiley
Mr. Joshua L. Smiley
President, Chief Operating Officer
President, Chief Operating Officer
86.60K
+10000.00%
Mr. William David (Bill) Lis
Mr. William David (Bill) Lis
Independent Director
Independent Director
35.11K
-2983.00%
Dr. Yajing Chen, Ph.D.
Dr. Yajing Chen, Ph.D.
Chief Financial Officer
Chief Financial Officer
17.44K
-240.00%
Dr. Ying (Samantha) Du, Ph.D.
Dr. Ying (Samantha) Du, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Ms. Leung (Nisa Bernice) Wing-Yu
Ms. Leung (Nisa Bernice) Wing-Yu
Independent Director
Independent Director
--
--
Detalhamento da receita
Moeda: USDAtualizado em: ter, 6 de jan
Moeda: USDAtualizado em: ter, 6 de jan
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
Por EmpresaUSD
Nome
Receita
Proporção
ZEJULA
42.43M
36.78%
VYVGART
27.73M
24.03%
NUZYRA
15.43M
13.38%
Optune
12.66M
10.97%
QINLOCK
8.90M
7.72%
Outro
8.21M
7.12%
Por RegiãoUSD
Nome
Receita
Proporção
China (Mainland)
116.09M
0.00%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
ZEJULA
42.43M
36.78%
VYVGART
27.73M
24.03%
NUZYRA
15.43M
13.38%
Optune
12.66M
10.97%
QINLOCK
8.90M
7.72%
Outro
8.21M
7.12%
Distribuição de ações
Atualizado em: sáb, 7 de fev
Atualizado em: sáb, 7 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Capital World Investors
5.39%
Fidelity Management & Research Company LLC
3.79%
Norges Bank Investment Management (NBIM)
3.41%
ClearBridge Investments, LLC
3.12%
RTW Investments L.P.
2.03%
Outro
82.26%
Investidores
Investidores
Proporção
Capital World Investors
5.39%
Fidelity Management & Research Company LLC
3.79%
Norges Bank Investment Management (NBIM)
3.41%
ClearBridge Investments, LLC
3.12%
RTW Investments L.P.
2.03%
Outro
82.26%
Tipos de investidores
Investidores
Proporção
Investment Advisor
15.68%
Investment Advisor/Hedge Fund
12.47%
Sovereign Wealth Fund
3.58%
Hedge Fund
2.94%
Individual Investor
1.78%
Private Equity
1.44%
Venture Capital
1.12%
Research Firm
0.61%
Pension Fund
0.02%
Outro
60.34%
Participação acionária institucional
Atualizado em: qua, 21 de jan
Atualizado em: qua, 21 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q4
280
37.42M
42.38%
--
2025Q4
369
40.92M
36.54%
-16.68M
2025Q3
372
46.61M
41.70%
-15.37M
2025Q2
394
60.58M
54.15%
-11.96M
2025Q1
453
59.51M
53.68%
-14.18M
2024Q4
446
60.80M
55.47%
-4.29M
2024Q3
439
51.45M
51.99%
-10.14M
2024Q2
454
47.04M
47.66%
-14.67M
2024Q1
465
46.22M
46.47%
-13.77M
2023Q4
497
46.31M
46.92%
-16.57M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Capital World Investors
6.08M
5.43%
+41.48K
+0.69%
Sep 30, 2025
Fidelity Management & Research Company LLC
4.28M
3.82%
-610.67K
-12.50%
Sep 30, 2025
ClearBridge Investments, LLC
3.52M
3.14%
-492.62K
-12.28%
Sep 30, 2025
RTW Investments L.P.
2.29M
2.05%
-3.25M
-58.62%
Sep 30, 2025
Janus Henderson Investors
2.05M
1.83%
-148.32K
-6.75%
Sep 30, 2025
Wellington Management Company, LLP
1.72M
1.53%
+341.49K
+24.80%
Sep 30, 2025
Frazier Life Sciences Management, L.P.
1.63M
1.45%
+319.18K
+24.40%
Sep 30, 2025
Baron Capital Management, Inc.
1.37M
1.22%
-216.57K
-13.64%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Tema Oncology ETF
1.67%
ALPS Medical Breakthroughs ETF
1.19%
Virtus LifeSci Biotech Products ETF
0.97%
Invesco Golden Dragon China ETF
0.58%
National Security Emerging Markets Index ETF
0.39%
iShares Biotechnology ETF
0.18%
Capital Group New Geography Equity ETF
0.15%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.12%
ActivePassive International Equity ETF
0.03%
Ver Mais
Tema Oncology ETF
Proporção1.67%
ALPS Medical Breakthroughs ETF
Proporção1.19%
Virtus LifeSci Biotech Products ETF
Proporção0.97%
Invesco Golden Dragon China ETF
Proporção0.58%
National Security Emerging Markets Index ETF
Proporção0.39%
iShares Biotechnology ETF
Proporção0.18%
Capital Group New Geography Equity ETF
Proporção0.15%
ProShares Ultra Nasdaq Biotechnology
Proporção0.12%
Invesco Nasdaq Biotechnology ETF
Proporção0.12%
ActivePassive International Equity ETF
Proporção0.03%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
